Welcome to Multibagg AI
Log in to access personalized features
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stock
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
19020.25 | 24,345 Cr | 66.88 | 12.99 | 0.18 | 19.42 | 23.57 | 12.42 | ||
4708.70 | 21,456 Cr | 29.70 | 5.11 | 1.60 | 17.19 | 23.02 | 14.68 | ||
843.80 | 20,878 Cr | 31.52 | 4.42 | 0.21 | 11.70 | 13.63 | 8.58 | ||
8167.90 | 20,420 Cr | 108.89 | 23.40 | 0.44 | 21.49 | 25.53 | 9.43 | ||
2616.70 | 19,939 Cr | 31.09 | 5.56 | 0.15 | 17.88 | 22.30 | 16.06 | ||
1402.85 | 19,400 Cr | 31.32 | 4.97 | 0.51 | 15.87 | 13.27 | 8.79 | ||
1690.10 | 19,371 Cr | -398.49 | 3.32 | 0.00 | -1.10 | 0.55 | -0.59 | ||
| Median: 7 Co. | — | 2616.70 | 20,420 Cr | 31.32 | 5.11 | 0.21 | 17.19 | 22.30 | 9.43 |
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Granules India Ltd (GRANULES) is currently trading at 853.15 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Granules India Limited is a vertically integrated pharmaceutical company specializing in Active Pharmaceutical Ingredient (API), Pharmaceutical Formulation Intermediates (PFI), and Finished Dosage (FD). Known for its leadership in off-patent drugs, it serves global branded and generic pharma firms with core products like Paracetamol and Ibuprofen. In Q3 FY26, Granules India reported a 22% year-over-year revenue growth, driven mainly by the Finished Dosage segment in North America and Europe. Their EBITDA also saw a meaningful jump of 34% year-over-year, signifying improved operating leverage. The company's strategic expansions include significant market penetration in Europe achieving a 131% year-over-year revenue growth in the region. They hold a leading position in 25% of their US product portfolio and received key GMP certifications, bolstering their regulatory compliance. Granules India is actively engaged in R&D, noted for their strides in peptide chemistry and controlled substances. They have made advances like the tentative approval of Amphetamine ER in the US market, asserting their innovative pathway. The management expressed confidence in resolving FDA concerns at their Gagillapur site. Concurrently, they are expanding geographical reach and strategic areas like peptides, complex generics, and sustainability efforts, maintaining robust governance and supply chain resilience.
Over the past 52 weeks, Granules India Ltd has traded between a low of ₹433.00 and a high of ₹910.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Granules India Ltd has a market capitalization of approximately 20,878.13. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Granules India Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 31.52 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 20,878.13 Cr, Granules India Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Granules India Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Granules India Ltd is 31.52. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Revenue rose 22% to ₹1,476.8 crore, EBITDA grew 37% to ₹338.9 crore, and PAT increased 60% to ₹180 crore; gross margin was 65.6%.
Granules said its US subsidiary GPI received USFDA approval for an ANDA for Lisdexamfetamine Dimesylate chewable tablets, a generic medication used to treat ADHD.
Granules said its US subsidiary GPI received tentative USFDA approval for its ANDA for Amphetamine Extended-Release Tablets.
The stock moved up after Granules India said its US subsidiary received a USFDA Establishment Inspection Report (EIR) for the Chantilly facility with a Voluntary Action Indicated (VAI) classification.
Bearish
2
Neutral
8
Bullish
4
Bearish
12
Neutral
8
Bullish
26
Bearish
10
Neutral
0
Bullish
22
Granules India Limited is a vertically integrated pharmaceutical company specializing in Active Pharmaceutical Ingredient (API), Pharmaceutical Formulation Intermediates (PFI), and Finished Dosage (FD). Known for its leadership in off-patent drugs, it serves global branded and generic pharma firms with core products like Paracetamol and Ibuprofen.
In Q3 FY26, Granules India reported a 22% year-over-year revenue growth, driven mainly by the Finished Dosage segment in North America and Europe. Their EBITDA also saw a meaningful jump of 34% year-over-year, signifying improved operating leverage.
The company's strategic expansions include significant market penetration in Europe achieving a 131% year-over-year revenue growth in the region. They hold a leading position in 25% of their US product portfolio and received key GMP certifications, bolstering their regulatory compliance.
Granules India is actively engaged in R&D, noted for their strides in peptide chemistry and controlled substances. They have made advances like the tentative approval of Amphetamine ER in the US market, asserting their innovative pathway.
The management expressed confidence in resolving FDA concerns at their Gagillapur site. Concurrently, they are expanding geographical reach and strategic areas like peptides, complex generics, and sustainability efforts, maintaining robust governance and supply chain resilience.
Pharmaceuticals & Biotechnology
Pharmaceuticals
20,878 Cr
Low Risk
31.5
37.2
1.4
4.4
910.00
433.00
Sales CAGR
Profit CAGR
ROE
ROCE
Earnings Call/Transcript
Granules India Ltd uploaded the transcript of its Q1 FY27 earnings call (held July 21, 2026). Reported strongest Q1: Revenue ~INR1,477 crore (+22% YoY), EBITDA INR339 crore (+37%), PAT INR180 crore (+60%), net debt ~0.07x; Gagillapur remediation nearly complete.
Earnings Call/Transcript
Granules India Ltd posted the transcript of its Q1 FY27 earnings call (held July 21, 2026). Reported Q1 revenue ₹1,477 crore (+22% YoY), EBITDA ₹339 crore (+37%), PAT ₹180 crore (+60%), near-zero net debt and remediation updates.
Earnings Call/Transcript
Granules India Ltd uploaded the audio recording of its Q1 FY27 earnings conference call on the company's website. Document dated July 22, 2026.
Earnings Call/Transcript
Granules India uploaded the audio recording of its Q1 FY27 earnings conference call on the company's website and provided the link for access.
